Cargando…
Recent Findings in the Posttranslational Modifications of PD-L1
Immune checkpoint therapy, such as the reactivation of T-cell activity by targeting programmed cell death 1 (PD-1) and its ligand PD-L1 (also called B7-H1 and CD274) has been found pivotal in changing the historically dim prognoses of malignant tumors by causing durable objective responses. However,...
Autores principales: | Li, Shu-Man, Zhou, Jie, Wang, Yun, Nie, Run-Cong, Chen, Jie-Wei, Xie, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199566/ https://www.ncbi.nlm.nih.gov/pubmed/32377193 http://dx.doi.org/10.1155/2020/5497015 |
Ejemplares similares
-
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
por: Yu, Xinfang, et al.
Publicado: (2021) -
Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
por: Horita, Henrick, et al.
Publicado: (2017) -
Posttranslational Modifications in Ferroptosis
por: Wei, Xiang, et al.
Publicado: (2020) -
Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
por: Nie, Run-Cong, et al.
Publicado: (2021) -
Recent Development of Genetic Code Expansion for Posttranslational Modification Studies
por: Chen, Hao, et al.
Publicado: (2018)